首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Prodrugs of butyric acid. Novel derivatives possessing increased aqueous solubility and potential for treating cancer and blood diseases.
【24h】

Prodrugs of butyric acid. Novel derivatives possessing increased aqueous solubility and potential for treating cancer and blood diseases.

机译:丁酸的前药。具有增加的水溶性和治疗癌症和血液疾病潜力的新型衍生物。

获取原文
获取原文并翻译 | 示例
           

摘要

The synthesis and biological activities of acidic, basic and neutral types of butyric acid (BA) prodrugs possessing increased aqueous solubility are described. The compounds are butyroyloxyalkyl derivatives of carboxylic acids, which possess functionalities suitable for aqueous solubilization. The anticancer activity of the prodrugs in vitro was evaluated by examining their effect on the growth of human colon, breast and pancreatic carcinoma cell lines, and their solubility in aqueous media was determined. The most promising compounds, with respect to activity and solubility, were found to be the butyroyloxymethyl esters of glutaric 2a and nicotinic acids 4a and phosphoric acid as its diethyl ester 10a, which displayed IC(50) values of 100 microM or lower. These prodrugs are expected to release formaldehyde upon metabolic hydrolysis. The corresponding butyroyloxyethyl esters (2b, 4b and 10b) that release acetaldehyde upon metabolism were significantly less potent. A similar correlation was observed for growth inhibition of the human prostate carcinoma cell lines PC-3 and LnCap and for induction of differentiation and apoptosis in the human myeloid leukemia cell line HL-60. The higher biological activity of the formaldehyde-releasing prodrugs 2a and 10a was further confirmed when induction of hemoglobin (Hb) synthesis in the human erythroleukemic cell line K562 was measured. Moreover, a therapeutic index (IC(50)/ED(50)) of ca. 5 was observed. The acute i.p. toxicity LD(50) in mice for 2a, 2b, 10a and 10b was similar and in the range of 400-600 mg kg(-1). The results obtained support the potential use of the butyric acid prodrugs for the treatment of neoplastic diseases and beta-globin disorders.
机译:描述了具有增加的水溶性的酸性,碱性和中性类型的丁酸(BA)前药的合成和生物活性。该化合物是羧酸的丁酰氧基烷基衍生物,其具有适合于水溶性溶解的官能度。通过检查前药对人结肠癌,乳腺癌和胰腺癌细胞系生长的影响来评估前药的体外抗癌活性,并确定其在水介质中的溶解度。就活性和溶解度而言,最有前途的化合物被发现是戊二酸2a和烟酸4a的丁酰氧基甲基酯和磷酸作为其二乙酯10a的磷酸,其IC(50)值等于或小于100 microM。预期这些前药在代谢水解后会释放甲醛。代谢时释放乙醛的相应丁酰氧基乙基酯(2b,4b和10b)的效力明显较低。在人类前列腺癌细胞系PC-3和LnCap的生长抑制以及在人类髓样白血病细胞系HL-60的诱导分化和凋亡中观察到相似的相关性。当测量人红白血病细胞系K562中血红蛋白(Hb)合成的诱导时,进一步证实了释放甲醛的前药2a和10a具有更高的生物活性。此外,治疗指数(IC(50)/ ED(50))约为3。观察到5。急性腹膜炎毒性对于小鼠2a,2b,10a和10b的LD(50)相似,范围为400-600 mg kg(-1)。获得的结果支持了丁酸前药在肿瘤疾病和β-珠蛋白疾病治疗中的潜在用途。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号